FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Draft Guide on Pharmacokinetic Analyses Format and Content

[ Price : $8.95]

Federal Register Notice: FDA posts a draft guidance on Physiologically Based Pharmacokinetic Analyses Format and Content.

Regulatory Review Period for BMSs Opdivo

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Bristol Myers Squibbs lung cancer therapy Opdivo (nivolum...

Draft Guidance on Pharmacokinetic Analyses Format/Content

[ Price : $8.95]

FDA releases a draft guidance on Physiologically Based Pharmacokinetic Analyses Format and Content that outlines the recommended ...

Fast Track for Staph Aureus Pneumonia Therapy

[ Price : $8.95]

FDA grants Arsanis fast track status for ASN100 for preventing Staphylococcus aureus pneumonia in mechanically ventilated patients...

Stem Cell Anecdotal Claims Worrisome: Califf

[ Price : $8.95]

FDA commissioner Robert Califf says that approval of stem-cell therapies should be based on scientific evidence.

Medtronic Recalls Neurovascular Products

[ Price : $8.95]

FDA says Medtronic has recalled four neurovascular products due to the risk of coating separation and detachment.

Cures Act Promises FDA $500 mil. More, Heads to Senate

[ Price : $8.95]

After a 392-26 passage in the House, the 21st Century Cures Act heads to the Senate and could see a vote as early as next week.

FDA Priority Review for Mercks Keytruda in Lymphoma

[ Price : $8.95]

FDA accepts for priority review a Merck supplemental BLA for Keytruda (pembrolizumab), an anti-PD-1 therapy for treating patients ...

FDA Clears BrightWater 510(k) for Nephroureteral Stent System

[ Price : $8.95]

FDA clears a BrightWater Medical 510(k) for the ConvertX Nephroureteral Stent System for treating ureteral obstructions, which pre...

FDA Updates REMS List

[ Price : $8.95]

FDA updates six REMS, including approval of a REMS for Novo Nordisks Xultophy.